New England Journal of Medicine· 2012Q1

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister, David D. Hurd et al.

1,150citations
Q1SCImago
2012year

Short summary

Lenalidomide maintenance therapy after autologous stem-cell transplantation significantly extended the median time to disease progression (46 vs. 27 months) and improved overall survival in multiple myeloma patients, despite increased toxicity and second cancers.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine